Atlas›Domain IX · Biomedical, neuro & digital›Guide 079
Guide IX-079

Paired VNS for stroke rehabilitation (Vivistim)

2021
A 25 · L 68 · M 717 interventions in the Trinity explorer
Client cardCompare
[source: …] where a claim comes from[uncertain] not confirmed in a primary source[synthesis] the writer's reconstruction

1. Introduction

Version followed: the Vivistim Paired VNS System as approved by the US FDA (PMA P210007, decision date 27 August 2021) and delivered as in the VNS-REHAB pivotal trial (Dawson et al., Lancet 2021) and its long-term follow-ups; regulatory and company status as of October 2026 per the FDA PMA database and the manufacturer's investor pages.

What it is. Paired vagus nerve stimulation (VNS) for stroke rehabilitation is an implanted, prescription-only device treatment combined with intensive arm rehabilitation. A pulse generator is placed under the skin of the chest and a lead runs under the skin to electrodes on the left vagus nerve in the neck. During rehabilitation sessions, a treating rehabilitation therapist triggers a brief burst of stimulation in time with each practised movement; later, the patient can start stimulation at home with a magnet while doing a prescribed home exercise programme. [source: FDA announcement via BioSpace 2021; FDA PMA P210007; Dawson et al. 2021]

Indication (FDA). The FDA approval order states the device stimulates the vagus nerve during rehabilitation therapy to reduce upper extremity motor deficits, for chronic ischaemic stroke patients with moderate to severe arm impairment. It is not approved for other uses (for example haemorrhagic stroke, leg or walking deficits, depression, or acute stroke). [source: FDA PMA P210007; BioSpace 2021]

Core idea of how change happens. The developers' rationale is that vagus nerve stimulation, delivered at the moment a movement is practised, strengthens the brain's learning response to that specific movement, so that intensive task practice produces more motor recovery than practice alone. The company describes this as combining targeted stimulation with functional movement to promote neuroplasticity. The stimulation does nothing useful without the practice: the active ingredient is the pairing. [source: Mobia Medical investor FAQs; Dawson et al. 2021]

Who delivers it. Candidacy is assessed by the stroke/neurology or rehabilitation medicine team; the device is implanted by a surgeon (in reported US programmes, a neurosurgeon) usually as an outpatient procedure; in-clinic paired therapy is delivered by occupational therapists or physical therapists; device programming is done by the clinical team with clinician software and a wireless transmitter, which patients do not use. [source: BioSpace 2021; AdventHealth 2023] In the US, occupational therapists are licensed by state boards and certified via NBCOT (professional body AOTA); physical therapists are licensed by state boards (professional body APTA). In the UK, occupational therapists and physiotherapists are regulated by the HCPC. [uncertain: not verified]

The psychotherapist's place. A psychotherapist does not select patients for, deliver, or adjust this treatment. The psychotherapist works alongside the treating team on decision support, adjustment to stroke and disability, mood after stroke, motivation for long-term home practice and collaboration. This guide is written for that role. For VNS as a treatment for depression or epilepsy (a different indication, device and pathway), see entry 019 Vagus nerve stimulation. [synthesis]

Regulatory and evidence status (as of October 2026)

  • United States: FDA premarket approval (PMA P210007), decision date 27 August 2021, with Breakthrough Device designation; product code QPY, generic name "stimulator, autonomic nerve, implanted for stroke rehabilitation". The PMA database lists later supplements, so current labelling may differ from the original. [source: FDA PMA P210007; BioSpace 2021]
  • Company: MicroTransponder, Inc. changed its corporate name to Mobia Medical, Inc. effective 24 February 2026; the product name Vivistim is unchanged. Commercial launch was in 2023; the company reported more than 1,000 systems implanted by end of 2025. [source: Mobia Medical investor FAQs; MedTech Dive, 5 May 2026]
  • Reimbursement (US): CMS transitional pass-through payment ran 2023–2025 and has expired; most commercial payers are reported to consider the device experimental or investigational and to require prior authorisation, with some coverage denials. [source: MedTech Dive, 5 May 2026]
  • Outside the US: although the pivotal trial ran partly in the UK, no CE marking, UKCA marking, NICE guidance or other national approval was found; the manufacturer describes it as an FDA-approved solution only. [uncertain: not verified]
  • Evidence: VNS-REHAB, a randomised, triple-blind, sham-controlled pivotal trial at 19 stroke rehabilitation services in the UK and USA, enrolled participants from 2 October 2017 to 12 September 2019 (108 implanted; 53 active, 55 sham). Arm impairment scores improved more with active pairing immediately after in-clinic therapy, and at 90 days 47% versus 24% had a clinically meaningful response. Long-term follow-ups report gains maintained at one year (Stroke, 2025, as reported in trade press) and two years (Kimberley et al., Neurology 2026), without a control comparison in those phases. [source: Dawson et al. 2021; NeuroNews International 2025; Kimberley et al. 2026]

2. Framework

This is a medical device pathway, not a psychotherapy; the phases below are the treatment pathway as sources describe it, with the psychotherapist's tasks alongside each. Stimulation settings and session-dose details are set by the treating team and are not described here. [synthesis]

Phase 1: Referral and candidacy assessment.

  • Goal (team): decide whether the person fits the indication (chronic ischaemic stroke, moderate to severe arm impairment, some active wrist or finger movement in the trial) and has no contraindication (prior vagotomy) or unresolved precaution. [source: FDA PMA P210007; Dawson et al. 2021; Mobia Medical investor FAQs]
  • Psychotherapist: decision support, realistic expectations, mood screening, readiness for a demanding course of practice. [synthesis]
  • Moving on: the medical team, not the psychotherapist, decides candidacy; insurance prior authorisation often comes first in the US. [source: MedTech Dive 2026]

Phase 2: Implantation.

  • Goal (team): surgical placement of the generator in the chest and lead on the left vagus nerve in the neck, under general anaesthesia in the trial; reported US programmes do this as outpatient surgery. [source: Dawson et al. 2021; AdventHealth 2023]
  • Psychotherapist: pre-surgical anxiety, coping with recovery from the wound, noticing post-operative problems to pass on. [synthesis]
  • Moving on: clinic therapy typically begins once the wound has healed (one to two weeks after surgery in one reported programme). [source: AdventHealth 2023]

Phase 3: In-clinic paired rehabilitation.

  • Goal (team): a time-limited block of outpatient sessions, several per week over about six weeks in the trial and in a reported programme, of intensive, high-repetition, individualised, task-based, progressive arm practice, with the therapist pairing stimulation to the movements. [source: Dawson et al. 2021; AdventHealth 2023]
  • Psychotherapist: fatigue, frustration, motivation, mood, family strain; keep psychological sessions from competing with the rehab schedule. [synthesis]
  • Moving on: completion of the in-clinic block and reassessment by the rehab team.

Phase 4: Home programme.

  • Goal (team): daily therapist-prescribed home exercises using the same principles, with patient-activated stimulation by magnet; in the trial, therapists made regular phone check-ins on adherence and intensity. Some programmes start home use during the clinic block. [source: Dawson et al. 2021; AdventHealth 2023; BioSpace 2021]
  • Psychotherapist: this is the phase where psychological work most affects outcome: habit-building, motivation, problem-solving barriers, mood. [synthesis]

Phase 5: Long-term use and ending.

  • Goal (team): continued self-initiated practice; periodic follow-up; device-related decisions (such as continued use or removal) stay with the medical team. The two-year follow-up notes that how much people practised in the long term was poorly documented. [source: Kimberley et al. 2026]
  • Psychotherapist: maintaining practice, accepting a plateau, identity and role adjustment, relapse prevention for mood. [synthesis]

Typical psychotherapy format alongside. No source specifies a psychotherapy schedule for this pathway. A practical pattern is one or two decision-support sessions before implantation, brief check-ins (in person or by video) during the clinic block, and more regular sessions in the home phase, adapted for fatigue, aphasia and cognitive change. [synthesis]

3. Guiding principles

  • Stay in role. The rehab team owns candidacy, programming, the exercise plan and device use; you own the psychological work. Practical meaning: never advise on how or when to use the magnet, how much to practise, or whether to have the device; route those questions to the treating therapist or physician. [synthesis]
  • The pairing is the treatment. Benefit depends on practice, not on the implant alone. Practical meaning: frame home practice as the active ingredient and treat motivation and habit as core targets. [source: Dawson et al. 2021; synthesis]
  • Honest expectations. Average gains in the trial were modest, and responses varied. Practical meaning: help the client hold hope and realism together; explore what a meaningful gain would be in daily life rather than a cure. [source: Dawson et al. 2021; synthesis]
  • Mood is part of the labelling, not an aside. The labelling lists depression or suicidality and certain psychiatric and bipolar disorders as conditions to discuss with providers, and low mood is among reported adverse events; the trial excluded people with high depression scores at screening. Practical meaning: screen, monitor and pass concerns to the team; do not assume low mood is "just adjustment". [source: BioSpace 2021; Dawson et al. 2021]
  • Post-stroke depression is common and consequential. About one third of stroke survivors have depression at any one time, linked to poorer recovery and function. Practical meaning: treat mood work as directly supporting rehabilitation. [source: AHA Top Things to Know, Towfighi et al. 2016]
  • Informed choice, not persuasion. Surgery, cost and uncertain insurance coverage are real burdens. Practical meaning: support the client's own decision, including a decision not to proceed. [source: MedTech Dive 2026; synthesis]
  • Collaborate with consent. Share information with the rehab team only with the client's agreement (or as law requires for risk). Practical meaning: agree at the outset what you will share and how. [synthesis]
  • Adapt to the person after stroke. Aphasia, fatigue, cognitive change and reduced mobility shape every session. Practical meaning: shorter sessions, written summaries, simple language, caregiver involvement when the client wants it. [synthesis]
  • Not a depression treatment. Paired VNS for stroke is not indicated for mood; do not conflate it with VNS for depression (entry 019). Practical meaning: correct the misunderstanding if a client hopes the implant will lift mood. [source: FDA PMA P210007; synthesis]

4. Intervention inventory

Part A describes how the treating team delivers paired VNS, at a descriptive level only, so that you can explain it accurately and recognise problems. Part B is the psychotherapist's own work. Nothing here is a protocol: stimulation settings, exercise doses and device instructions come only from the treating team and the current labelling.

Part A. How the treatment is delivered (descriptive)

A1. Candidacy assessment and referral

  • Purpose: decide whether paired VNS fits the person.
  • Steps (as sources describe): the stroke, neurology or rehabilitation medicine team confirms chronic ischaemic stroke with moderate to severe arm impairment; the trial additionally required some active wrist or finger movement and excluded severe sensory loss, severe spasticity and a high depression score at screening; prior (bilateral or left cervical) vagotomy is a contraindication; conditions to discuss with providers include other brain stimulation, diathermy, depression or suicidality, certain psychiatric and bipolar disorders, prior brain surgery or CNS injury, progressive neurological disease, cardiac arrhythmia, autonomic disorders, respiratory disease, ulcers, vasovagal syncope and pre-existing hoarseness. In the US, insurance prior authorisation is commonly needed. [source: Dawson et al. 2021; BioSpace 2021; Mobia Medical investor FAQs; MedTech Dive 2026]
  • Example language (illustrative): "The stroke team will decide whether this device suits you. What I can do is help you work out your questions for them and what matters to you in deciding."
  • Watch for: a client told they are "not a candidate" (grief, anger, shame); clients seeking the device for leg, speech or mood problems it is not approved for; a history of bipolar disorder or recent suicidality the team may not know about (encourage the client to tell them, or share with consent).

A2. Implantation surgery

  • Purpose: place the generator under the chest skin and the lead on the left vagus nerve in the neck.
  • Steps (as sources describe): in the trial, surgery was under general anaesthesia through a small incision in a neck crease, with the lead tunnelled under the skin to a chest pocket; a reported US programme performs it as outpatient surgery by neurosurgeons. Risks the manufacturer lists include post-operative pain, hoarseness, bruising, swelling, coughing, throat irritation and infection. In the trial, implant-related adverse events (mostly post-operative pain) were common in both groups, and one serious surgical event, vocal cord paresis, occurred and resolved after several weeks. [source: Dawson et al. 2021; AdventHealth 2023; Mobia Medical investor FAQs]
  • Example language (illustrative): "It's normal to feel nervous about an operation on your neck. Would it help to list what you want to ask the surgeon, including what recovery looks like and who to call if something seems wrong?"
  • Watch for: voice changes, swallowing difficulty, wound redness or discharge, fever, or pain that is worsening rather than settling: encourage prompt contact with the surgical team. Pre-surgical anxiety that tips into avoidance.

A3. In-clinic paired rehabilitation

  • Purpose: intensive arm practice with stimulation paired to each movement.
  • Steps (as sources describe): an occupational or physical therapist delivers outpatient sessions over several weeks; practice is high-repetition, individualised, task-based, functional and progressive (for example reaching and grasping, flipping objects, opening containers), with objects, movements and setting adjusted to keep tasks challenging and motivating; the therapist times stimulation to the movements using a wireless transmitter and clinician software. FDA-reported adverse events across the programme include dysphonia, hoarseness, bruising, falls, pain (general and muscle), low mood, fracture, headache, rash, dizziness, throat irritation, urinary tract infection and fatigue. [source: Dawson et al. 2021; AdventHealth 2023; BioSpace 2021]
  • Example language (illustrative): "These sessions sound long and tiring. How are you coping with the effort, and how are you feeling at the end of the day?"
  • Watch for: exhaustion, frustration with slow progress, falls or near-falls, low mood or tearfulness emerging during the block, and voice or throat symptoms (pass on to the rehab therapist).

A4. Home exercise programme

  • Purpose: continue paired practice at home to maintain and extend gains.
  • Steps (as sources describe): the rehab therapist prescribes daily home exercises on the same principles; the patient starts a timed stimulation session by passing a magnet over the implant site while exercising or doing daily tasks; in the trial, therapists phoned regularly to check adherence and intensity. Physicians direct training on home use. [source: Dawson et al. 2021; BioSpace 2021; AdventHealth 2023]
  • Example language (illustrative): "Your therapist set up the exercises and how to use the magnet. My part is helping you make the practice fit into your days. What gets in the way?"
  • Watch for: practice dropping off after the clinic block ends; confusion about magnet use (route to the rehab therapist, do not instruct); caregivers taking over or nagging.

A5. Long-term follow-up

  • Purpose: maintain gains and manage the device over time.
  • Steps (as sources describe): continued self-initiated home practice; follow-up studies report maintained gains at one and two years, but long-term practice amounts were poorly documented. Questions about MRI, other medical procedures, battery life or removal belong to the implanting team and current labelling. [source: Kimberley et al. 2026; NeuroNews International 2025] [uncertain: MRI conditions and device-life details not verified]
  • Example language (illustrative): "That's a good question for your device team; shall we write it down so you remember to ask?"
  • Watch for: a plateau experienced as failure; the client being told about other medical procedures without the device team being informed.

Part B. The psychotherapist's interventions

B1. Recognising when to suggest a medical or rehabilitation review

  • Purpose: help a client who might benefit, or who has questions, reach the right team.
  • Steps: (1) Notice persisting arm weakness after ischaemic stroke that limits valued activities. (2) Ask whether they have discussed rehabilitation options with their stroke or rehab physician. (3) Mention that device-assisted options exist and that the medical team decides suitability. (4) Offer to help prepare questions. (5) With consent, write to the GP/primary care physician or rehab team. [synthesis]
  • Example language (illustrative): "You've mentioned how much the weakness in your arm still limits you. Have you talked recently with your rehab doctor about what other options there are? Some people ask about device-assisted rehabilitation; they would be the ones to say whether it suits you."
  • Watch for: do not promote the device or imply benefit; note whether the client hears this as hope or pressure; check stroke type (indication is ischaemic stroke only).

B2. Psychoeducation about paired VNS

  • Purpose: an accurate, simple understanding that supports decision-making and adherence.
  • Steps: (1) Ask what they already know and where they heard it. (2) Explain in plain language: an implant in the chest and neck, stimulation paired with practice, clinic phase then home phase. (3) Emphasise that practice is essential. (4) Clarify it is approved for arm deficits after chronic ischaemic stroke, not for mood, speech or walking. (5) Distinguish it from VNS for depression (entry 019). (6) Use written summaries and check understanding with teach-back, especially with aphasia or cognitive change. [source: FDA PMA P210007; BioSpace 2021; synthesis]
  • Example language (illustrative): "As I understand it, the device gives your nerve a small signal at the same moment you practise a movement, to help the practice 'stick'. So the exercises are the real work. Does that match what the team told you?"
  • Watch for: magical expectations ("the implant will fix my arm"); misinformation from forums or marketing; aphasia masking misunderstanding (check with yes/no questions and pictures).

B3. Supporting informed consent and shared decision-making

  • Purpose: help the client make their own choice about surgery and a demanding programme.
  • Steps: (1) Clarify the client's values and goals (which daily activities matter most). (2) Help list questions for the team: expected benefit for someone like them, surgical risks, recovery, time commitment, travel, cost and insurance, what happens if they stop. (3) Explore pros and cons, including doing intensive rehabilitation without the device. (4) Check capacity-relevant understanding without making capacity judgments yourself; if you doubt capacity, raise it with the team. (5) Support the decision either way. [source: MedTech Dive 2026 on coverage; synthesis]
  • Example language (illustrative): "Let's put both sides on paper. What would make this worth it for you, and what would make it not worth it?"
  • Watch for: family pressure in either direction; financial strain from denied coverage; decisional regret later; clients who agree to please the team.

B4. Expectation-setting and adjustment to partial recovery

  • Purpose: protect against demoralisation when gains are modest or gradual.
  • Steps: (1) Elicit hoped-for outcomes. (2) Reflect that, in the trial, average gains were modest and varied between people (per the team's explanation). (3) Translate into personal, small, functional goals agreed with the rehab therapist. (4) Track meaningful moments (e.g. holding a cup) rather than only scores. (5) Work on grief for the pre-stroke body and identity, using your usual modality (e.g. acceptance-based or meaning-centred work). [source: Dawson et al. 2021; synthesis]
  • Example language (illustrative): "It sounds like part of you hopes for your old arm back, and part of you knows the change may be smaller. Both make sense. What would a small but real step look like?"
  • Watch for: all-or-nothing appraisals; comparisons with others in clinic; hopelessness after reassessment.

B5. Screening and monitoring mood after stroke

  • Purpose: detect post-stroke depression and anxiety early, since mood is listed in the labelling precautions and among reported adverse events, and depression is linked to poorer recovery.
  • Steps: (1) Ask about mood, sleep, appetite, interest and hopelessness at intake and at each phase change (before surgery, mid-clinic block, after the clinic block ends). (2) Use a validated, stroke-appropriate measure your service is licensed for; adapt for aphasia (observer-rated or visual formats). (3) Separate fatigue, apathy and emotionalism from depression where you can, while recognising overlap. (4) Share significant or worsening findings with the rehab team and physician, with consent. (5) Offer evidence-based psychological treatment and, where indicated, suggest a medical review for mood; never comment on medication choices. [source: AHA Top Things to Know (Towfighi et al. 2016); BioSpace 2021; Dawson et al. 2021; synthesis]
  • Example language (illustrative): "Low mood is very common after a stroke and can make rehab harder. The device team also asks to know about mood. Over the past couple of weeks, how often have you felt down or lost interest in things?"
  • Watch for: new or worsening low mood after implantation or after the clinic block ends (loss of structure and therapist contact); withdrawal from practice as an early sign; history of bipolar disorder (any mood elevation should be passed on promptly).

B6. Suicide risk assessment and safety planning

  • Purpose: respond to suicidality, which the labelling names as a condition to discuss with providers.
  • Steps: (1) Ask directly about suicidal thoughts when mood is low or hopelessness appears, using your service's standard risk assessment. (2) Collaboratively write a safety plan (warning signs, coping steps, people to contact, professional and crisis contacts, making the environment safer through storage or removal of means). (3) Adapt the plan for physical disability and communication difficulties (large print, pictures, a caregiver copy with consent). (4) Inform the treating physician and team as your risk policy requires. (5) Follow up closely around disappointing reassessments. [source: BioSpace 2021 (labelling precautions); synthesis]
  • Example language (illustrative): "Sometimes when people feel this hopeless after a stroke, they think about not wanting to be alive. Has that been on your mind?"
  • Watch for: hopelessness tied to "the last option didn't work"; social isolation; caregiver burnout reducing support.

B7. Motivation and habit-building for home practice

  • Purpose: sustain the daily practice on which benefit depends, without changing the prescribed programme.
  • Steps: (1) Ask the rehab therapist (with consent) what the home programme is, so your work aligns. (2) Use motivational interviewing to explore the client's own reasons for practice and their ambivalence. (3) Link practice to valued activities (cooking, grandchildren, hobbies). (4) Build implementation intentions: when, where, after which daily cue. (5) Use self-monitoring the client chooses (a calendar tick, a phone reminder). (6) Problem-solve barriers: fatigue (time of day), pain, low mood, boredom, carer availability. (7) Review and celebrate small wins; normalise lapses. (8) Route any question about how much to practise or how to use the magnet to the rehab therapist. [source: Dawson et al. 2021 and Kimberley et al. 2026 on home-phase role; synthesis]
  • Example language (illustrative): "On a scale of 0 to 10, how important is the home practice to you right now? What makes it a 5 and not a 2?" / "What would make it easier to practise on the days you're tired?"
  • Watch for: practice treated as a chore imposed by others; guilt and avoidance after missed days; over-practising driven by anxiety or perfectionism (pass concerns about pain or overuse to the rehab therapist). It is working when practice is regular, self-initiated and tied to the client's own goals.

B8. Monitoring and passing on side effects and warning signs

  • Purpose: make sure physical problems reach the right clinician quickly.
  • Steps: (1) Know the adverse events the FDA and manufacturer list: hoarseness or voice change, throat irritation, coughing, pain, bruising, swelling, headache, dizziness, falls, fatigue, low mood, infection. (2) Ask briefly about these at check-ins. (3) Encourage the client to contact the implanting or rehab team; with consent, contact them yourself. (4) Urgent symptoms (breathing or swallowing difficulty, fainting, signs of wound infection, a fall with injury, a new stroke symptom) mean urgent medical care. [source: BioSpace 2021; Mobia Medical investor FAQs; synthesis]
  • Example language (illustrative): "Any changes in your voice, swallowing, the wound, or dizziness since the operation? Those are things your device team wants to hear about."
  • Watch for: clients minimising symptoms to stay in the programme; caregivers noticing changes the client does not.

B9. Collaboration with the rehabilitation team

  • Purpose: integrate psychological care with the rehab plan.
  • Steps: (1) Obtain written consent covering whom you contact and what you share. (2) Introduce yourself to the treating occupational or physical therapist and the physician. (3) Agree a simple channel for concerns (mood, risk, adherence barriers) and what they would like from you. (4) Align language and goals so the client hears one consistent message. (5) Share cognitive or communication adaptations that help sessions. (6) Document contacts. [synthesis]
  • Example language (illustrative, to a colleague): "I'm seeing your patient for adjustment and mood after stroke. With their consent, I'd like to make sure we're aligned on their goals for the home programme and agree how I flag any mood concerns."
  • Watch for: splitting (the client tells each clinician different things); role drift (being asked to "get them to comply"); confidentiality limits.

B10. Involving caregivers and family

  • Purpose: support the people who often make home practice possible and who carry strain.
  • Steps: (1) With the client's agreement, invite the carer to a joint session. (2) Clarify the carer's role in home practice as the rehab therapist defines it (prompting, setting up tasks), not as supervisor. (3) Address carer stress, expectations and conflict. (4) Signpost carer support. [synthesis]
  • Example language (illustrative): "How can your partner help in a way that feels like support rather than being checked on?"
  • Watch for: overprotection limiting the client's practice; criticism lowering mood; carer depression.

B11. Integrating psychotherapy before, during and after the treatment

  • Purpose: time psychological work to the pathway.
  • Steps: (1) Before: decision support (B3), expectations (B4), mood baseline (B5), surgical anxiety. (2) During the clinic block: brief, flexible contact that respects fatigue and the rehab timetable; avoid adding demanding homework. (3) Home phase: motivation and habits (B7), mood monitoring, re-engagement in valued activities (e.g. behavioural activation built around arm use where the rehab therapist agrees). (4) After: relapse prevention for mood, plateau acceptance, identity and role adjustment. [synthesis]
  • Example language (illustrative): "The clinic sessions are ending soon. People sometimes feel a bit lost when that structure goes. Shall we plan for that now?"
  • Watch for: the drop in contact and structure after the clinic block as a risk point for mood and practice.

B12. Adapting psychological work after stroke

  • Purpose: make your sessions accessible.
  • Steps: (1) Ask about aphasia, memory, attention and fatigue; seek the speech and language therapist's advice on communication with consent. (2) Use shorter sessions, one topic at a time, written or pictorial summaries, and teach-back. (3) Schedule around rehab sessions and fatigue peaks. (4) Ensure physical access. [synthesis]
  • Example language (illustrative): "I'll write down the one thing we agreed today so you have it at home. Can you tell me in your own words what it is?"
  • Watch for: nodding without understanding; fatigue late in sessions; frustration with word-finding.

5. Handling problems

The sources describe the device pathway, not psychological problems around it; all guidance in this section is [synthesis] unless a source is named.

  • Client wants your opinion on whether to have the implant. Do not recommend for or against. Return to their values and the team's information (B3); offer to help them get answers to open questions. (illustrative) "I can't say whether it's right medically, but I can help you work out what matters most to you in deciding."
  • Not eligible or coverage denied. Treat as a loss; validate anger and grief; explore other routes the rehab team can advise on (including intensive rehabilitation without a device); watch for hopelessness (B6). Reported prior-authorisation hurdles and denials are common in the US. [source: MedTech Dive 2026]
  • Stuck: "I'm not improving." Separate objective reassessment (the rehab team's job) from felt progress; encourage the client to ask the team how they are doing; shift to functional micro-goals (B4); screen mood (B5). Do not interpret the device as failing or suggest changes to it.
  • Overwhelm and fatigue during the clinic block. Reduce your own demands (shorter or fewer sessions), teach brief pacing and recovery strategies, and encourage the client to tell the rehab therapist, who can adjust the plan.
  • Non-adherence to home practice. Explore ambivalence without blame (B7); identify concrete barriers; check mood, pain and cognition; with consent, let the rehab therapist know so they can review the programme. Never give your own exercise or magnet instructions.
  • Over-practising or pain. Anxiety-driven over-effort can lead to pain or falls (falls and pain are among reported adverse events [source: BioSpace 2021]); explore the beliefs driving it and pass physical concerns to the rehab therapist.
  • New or worsening low mood, or mood elevation. Assess (B5, B6); inform the physician and team with consent or as risk policy requires; for elevated mood in someone with a bipolar history, prompt medical review. The labelling lists depression or suicidality and bipolar disorder among conditions to discuss with providers. [source: BioSpace 2021]
  • Voice changes, throat symptoms, dizziness or fainting. Encourage same-day contact with the implanting team; urgent care for breathing or swallowing difficulty or fainting with injury (B8).
  • Confusion with VNS for depression. If a client hopes the implant will treat mood, explain that this device is approved for arm motor deficits only and that mood needs its own care; VNS for depression is a separate treatment and pathway (entry 019).
  • Rupture: the client feels you are "on the team's side". Acknowledge it, restate your role (their psychological wellbeing, not compliance), review consent to share, and ask what would restore trust.
  • Caregiver conflict over practice. Joint session focusing on roles (B10); reduce criticism; support carer wellbeing.
  • Ending the intensive phase. Plan for the loss of structure and therapist contact; agree a maintenance routine with the rehab therapist's input; schedule mood check-ins.
  • Do-it-yourself or non-approved stimulation. If a client mentions buying consumer "vagus nerve stimulators" or ear-clip devices to boost rehab, note that these are not the approved paired system, that their effects are not established by the trial evidence, and that they should discuss any such device with their physician and device team before use. [synthesis] [uncertain: evidence on consumer devices not reviewed here]
  • Questions you cannot answer (MRI safety, battery, removal, travel and security screening, other surgery): write them down with the client and route them to the implanting team and current labelling. [synthesis]

Sources

← Previous · IX-078Virtual-reality and exergame rehabilitationNext · IX-080 →Brain-computer-interface rehabilitation and neural interfaces